19:21 , Sep 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro and mouse studies identified a hedgehog pathway inhibitor that could help treat medulloblastoma. Optimization and testing in mouse fibroblast cell-based assays of a previously identified dihydrobenzooxazocin analog yielded a compound that...
19:58 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; cancer

INDICATION: Colitis; colorectal cancer Mouse studies suggest agonizing SHH signaling could help treat colitis and colitis-induced colorectal cancer. In a mouse model of acute colitis, heterozygous knockout of the SHH negative regulator PTCH1 decreased disease severity...
07:00 , Jun 13, 2016 |  BioCentury  |  Product Development

Basket cases

Both the Genentech Inc. unit of Roche and Novartis AG are using basket trials to study targeted cancer agents more efficiently. Genentech's initial forays could yield rare subpopulation data to bring its marketed therapies into...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Smoothened (SMO) Structural and cell culture studies suggest oxysterol-based inhibitors could help treat cancers driven by...
08:00 , Mar 5, 2012 |  BioCentury  |  Product Development

Mechanism matters

The different mechanisms by which the hedgehog pathway drives specific cancers could explain why Genentech Inc.'s Erivedge vismodegib received FDA approval for advanced basal cell carcinoma while Infinity Pharmaceuticals Inc.'s saridegib failed in pancreatic cancer. In...
07:00 , Jun 30, 2011 |  BC Innovations  |  Targets & Mechanisms

Smoother tumor targets

Texas researchers have identified two kinases-GRK2 and CKI-a-that are responsible for phosphorylating smoothened, the central player in the hedgehog signaling pathway.1 The findings could open a new front against the tumor-promoting pathway if sufficiently selective...
07:00 , Oct 14, 2010 |  BC Innovations  |  Cover Story

Smoothening resistance

Novartis AG researchers have uncovered three possible molecular causes for brain tumor resistance to inhibitors of Smoothened, which is a key component of the Hedgehog pathway.1 The pharma has used the discovery to devise combination...
07:00 , Aug 5, 2010 |  BC Innovations  |  Cover Story

Arsenic against the hedgehog

Researchers at the Stanford University School of Medicine have found that arsenic trioxide is able to antagonize the hedgehog pathway.1 The findings could open up hedgehog-driven solid tumors such as basal cell carcinoma and medulloblastoma...
07:00 , May 20, 2010 |  BC Innovations  |  Targets & Mechanisms

Glucocorticoids get Smoothened

Researchers at the Duke University School of Medicine have identified several FDA-approved glucocorticoids that also agonize a member of the hedgehog pathway called Smoothened and have shown that the drugs can stimulate the proliferation of...
07:00 , Sep 17, 2009 |  BC Innovations  |  Targets & Mechanisms

The Hedgehog's spine

The primary cilium, a lone spiky protrusion on the cell surface, once was thought to be a functionless vestige of humankind's unicellular past. However, genetic defects in the primary cilium turned out to be linked...